New results for adjuvant pembrolizumab in resected stage IIB and IIC melanoma suggest it will be become the standard treatment for high-risk early stage melanoma patients, according to Australian oncologists. Findings from the KEYNOTE-716 trial presented at ESMO 2021 showed that it decreased the risk of disease recurrence or death by 35% compared with placebo ...
New standard of care for high-risk early stage melanoma: adjuvant immunotherapy
By Michael Woodhead
22 Sep 2021